Program
Chimeric Antigen Receptor T-cells
Also written as “Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103”, “CAR T cells” and “CAR-T cells”.
Its studies are mostly in Glioma · Lymphoma, Non-Hodgkin · Colorectal Neoplasms · Leukemia, Myeloid, Acute · Carcinoma, Hepatocellular, led by 7 companies.
Drug pageChimeric Antigen Receptor T-cells: every studyMany companies study it; this page follows only the 8 they lead. All 68 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Tcelltech | 21 open or running | phase 1since Jun 15, 2024 | Jun 15, 2024 | none ahead |
| AGC Biologicsits history only | 10 open or running | phase 2since Aug 5, 2019 | Aug 5, 2019 | none ahead |
| Chongqing Precision Biotechits history only | 11 open or running | phase 1since Jun 12, 2022 | Jun 12, 2022 | none ahead |
| Imunopharm Technologyits history only | 10 open or running | phase 1since Jan 27, 2021 | Jan 27, 2021 | none ahead |
| Shanghai Cell Therapy Groupits history only | 11 open or running | phase 1since Oct 11, 2021 | Oct 11, 2021 | none ahead |
| Shanghai GeneChemits history only | 10 open or running | phase 2since Nov 6, 2016 | Nov 6, 2016 | none ahead |
| Suzhou Immunofoco Biotechnologyits history only | 11 open or running | phase 3since Jul 17, 2025 | Jul 17, 2025 | May 31, 2027phase 3 · NCT07103668 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Tcelltech only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 15, 2024First study: phase 1 study in GliomaFirst studyNCT06482905 · 52 planned · United States, China
- Nov 13, 2025Phase 1 study in Solid TumorsNCT07231081 · 85 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 Tcelltech leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07231081Solid Tumors · China | 1 | Suspended | Dec 20, 2027 | 85 |
| NCT06482905Glioma · United States, China | 1 | Recruiting | Sep 2026 | 52 |
How it is read
Names in the registry
- “Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103”, 2 entries
- “CAR T cells”, 2 entries
- “CAR-T cells”, 2 entries
- “MLM-CAR44.1 T-cells at day 0 Single intravenous infusion”, 1 entry
- “CAR-T cell”, 1 entry
Conditions, from the studies’ own filings
- Glioma, 1 study
- Lymphoma, Non-Hodgkin, 1 study
- Colorectal Neoplasms, 1 study
- Leukemia, Myeloid, Acute, 1 study
- Carcinoma, Hepatocellular, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.